[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608501":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":26,"responsibleParty":36,"collaborators":26,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":26,"enrollmentInfo":47,"targetDuration":26,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":26,"overallStatus":57,"whyStopped":26,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":26},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Performance of an antibiotic susceptibility test on agar medium","ACTIVE_COMPARATOR","Performance of an antibiotic susceptibility test on agar medium, with results expected between H18 and H24",[13],"Diagnostic Test: antibiotic susceptibility testing on agar medium",{"label":15,"type":16,"description":17,"interventionNames":18},"Antibiotic susceptibility testing performed using the Reveal technique","EXPERIMENTAL","Antibiotic susceptibility testing performed using the Reveal technique, with results available between the 4th and 6th hour (H4-H6) after blood culture positivity, allowing for rapid clinical categorization for the 23 antibiotics tested, along with their corresponding MICs.",[19],"Diagnostic Test: SPECIFIC REVEAL® Rapid AST system",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIAGNOSTIC_TEST","SPECIFIC REVEAL® Rapid AST system","The SPECIFIC REVEAL™ system uses biosensors capable of detecting volatile substances released by microorganisms during their growth. The detection of these volatile compounds by ultra-high-performance biosensors enables very early detection of bacterial growth compared with standard technologies based on visual systems (e.g. diffusion antibiogram or MICs determined by microdilution in liquid media) or optical density measurement systems (e.g. Vitek2)",[15],null,{"type":22,"name":28,"description":11,"armGroupLabels":29,"otherNames":26},"antibiotic susceptibility testing on agar medium",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Françoise Jauréguy","CONTACT","01 48 95 56 69","francoise.jaureguy@aphp.fr",{"type":37,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100608501","impact-of-real-time-mic-minimum-inhibitory-concentration-reporting-6-hours-on--lactam-prescription-in-cases-of-gram-negative-bacilli-bacteremia-in-icu-patients-in-real-life-settings-100608501",false,"NCT07202377","Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (\u003C6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings","CMIBActRéa","Inclusion Criteria:\n\n* Adult patients aged over 18 years\n* Patients with a positive blood culture for Gram-negative bacilli (Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii) with results reported on weekdays before 11:00 ante meridiem (AM)\n* Patients clinically suspected of infection\n* Treated with empirical antibiotic therapy including a β-lactam, among the standard list of antibiotics to be tested recommended by CASFM-EUCAST (European Committee on Antimicrobial Susceptibility Testing) for Enterobacterales\u002FPseudomonas and included in the Reveal Rapid AST System panel\n* Hospitalized in intensive care unit (ICU) for at least the next 24 hours\n* Written informed consent obtained from the patient or a relative for study participation (emergency consent)\n* Affiliated with the French social security system\n\nExclusion Criteria:\n\n* Patients receiving withdrawal or limitation of care\n* Patients with an expected survival prognosis of less than 72 hours\n* Patients with bloodstream infections caused by Gram-negative bacilli other than Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa\n* Patients treated with antibiotic therapy not including a β-lactam\n* Polymicrobial bloodstream infections\n* Pregnant or breastfeeding women\n* Patients under legal protection (guardianship or conservatorship)\n* Participation in another interventional research study","ALL","18 Years",{"count":48,"type":49},200,"ESTIMATED","INTERVENTIONAL",[52],"NA","Evaluate the impact of rapid, real-time (4 to 6 h) MIC reporting compared with the standard method (=diffusion antibiotic susceptibility testing) (18 to 24 h) on β-lactam prescribing in terms of the choice of molecule by the resuscitating clinician in the event of real-life Gram-negative Bacilli GNB bacteremia in the ICU.",[55,56],"Gram-negative Bacteremia","Intensive Care Patients","NOT_YET_RECRUITING","2025-09-29",{"date":60,"type":61},"2025-10-01","ACTUAL",{"date":63,"type":49},"2025-10",{"date":65,"type":49},"2026-11",{"name":5,"class":6}]